Serplulimab Approved by NMPA for Perioperative Gastric Cancer with tumour PD-L1 expression CPS ≥ 5, followed by adjuvant monotherapy
Dr. Jason Zhu, Executive Director and CEO of Henlius, stated:“The approval of serplulimab for perioperative gastric cancer marks another major milestone for Henlius as we continue to drive innovation based on ‘first principles’ and deepen our presence in gastrointestinal oncology. Centered on patient needs, this new post-operative chemotherapy-free regimen not only underscores our strong expertise in tumor immunotherapy, but also brings new hope for cure to patients undergoing perioperative treatment for gastric cancer. Looking ahead, we will continue to unlock the clinical potential of our innovative pipeline and accelerate our Globalization 2.0 strategy, with the goal of delivering high-quality innovative biologic medicines to benefit patients in China and around the world.”
Share:
More News
“FDA clearance of the IND for ORM-1153 is an important milestone for Orum, bringing another first-in-class DAC into the clinic and extending our approach into CD123-expressing hematologic malignancies,” said Olaf Christensen, M.D., Chief Medical Officer of Orum Therapeutics. “By combining cell-selective delivery with targeted protein degradation in a single molecule,
“We are excited to expand our clinical collaboration with Roche to evaluate a second KRAS combination with potential best-in-class MTA-cooperative PRMT5 inhibitor IDE892 for pancreatic cancer patients, where there remains a high unmet medical need. IDEAYA is advancing multiple rational combination strategies for the IDE892 program, including with MAT2A inhibitor
“These encouraging initial safety observations represent an important first step in the clinical evaluation of ZI-MA4-1 and our TCR-NK platform” said Namir Hassan, Chief Executive Officer of Zelluna. “The first patient received all three planned doses, and the independent committee’s recommendation enables us to continue recruitment at the first dose
“Receiving FTD is an important milestone for ERAS-0015 and reflects the urgent need for new therapies for patients with metastatic pancreatic cancer,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Together with the encouraging clinical activity and favorable tolerability observed to date, this FTD helps to position us